Skip to main content

Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries

Archives of Osteoporosis volume 11, Article number: 31 (2016) Cite this article

Abstract

Summary

Osteoporosis medications are recommended for elderly patients after a fragility fracture. However, we found substantial under-treatment in the post-fracture year, especially among patients who had not previously received such medications. Improved treatment of elderly patients experiencing fragility fractures is needed.

Introduction

Osteoporosis medications are recommended for elderly patients after a fragility fracture, but under-treatment is common. We determined osteoporosis medication use after fragility fractures and examined associated factors.

Methods

Our cohort included elderly (age ≥66 years) Medicare-enrolled patients who sustained fragility fractures January 1, 2008–December 31, 2011. Osteoporosis medication prescriptions were determined in the 12 months after the index fracture. Using multivariate logistic models, we examined the association between post-fracture osteoporosis medication use and predictors.

Results

Of 145,185 patients with fragility fractures (mean age 80.9 ± 7.8 years; 91.2 % white; 81.3 % female), 29.9 % sustained hip, 31.8 % vertebral, and 38.4 % non-hip-non-vertebral fractures. Overall, 30.4 % of the cohort received an osteoporosis medication in the 12-month post-fracture period. Of patients not receiving an osteoporosis medication in the pre-index period (n = 108,344), 14.9 % of all patients, 16.3 % of women, and 10.3 % of men received one in the post-fracture period. Corresponding values for patients receiving an osteoporosis medication in the pre-index period (n = 36,841) were 76.2, 76.5, and 72.2 %. Odds of post-fracture osteoporosis medication use were 68 % higher for women than for men. Osteoporosis diagnosis (odds ratio, 1.55; P < 0.0001) and bone-mineral-density tests before an index fracture (odds ratio, 1.24; P < 0.001) were associated with post-fracture osteoporosis medication use.

Conclusions

Less than one third of our cohort received an osteoporosis medication in the post-fracture year, when risk of a second fragility fracture is highest. In those not already previously treated with an osteoporosis medication, only about 1 in 7 patients received treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Marks R, Allegrante JP, MacKenzie CR, Lane JM (2003) Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev 2:57–93

    Article  PubMed  Google Scholar 

  2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475

    Article  PubMed  Google Scholar 

  3. Dempster DW (2011) Osteoporosis and the burden of osteoporosis-related fractures. Am J Manag Care 17(Suppl 6):S164–S169

    PubMed  Google Scholar 

  4. Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES (2007) Economic burden of osteoporosis-related fractures in Medicaid. Value Health 10:144–152

    Article  PubMed  Google Scholar 

  5. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179

    Article  CAS  PubMed  Google Scholar 

  6. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  CAS  PubMed  Google Scholar 

  7. North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 17:25–54

    Article  Google Scholar 

  8. Florence R, Allen S, Benedict L, Compo R, Jensen A, Kalogeropoulou D, Kearns A, Larson S,Mallen E, O'Day K, Peltier A, Webb B (2013) Diagnosis and treatment of osteoporosis. Institute for Clinical Systems Improvement. Available at: https://www.icsi.org/_asset/vnw0c3/osteo.pdf. Accessed September 27, 2016

  9. Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD (2014) Declining rates of osteoporosis management following fragility fractures in the US, 2000 through 2009. J Bone Joint Surg Am 96:e52

    Article  PubMed  Google Scholar 

  10. Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in US patients between 2002 and 2011. J Bone Miner Res 29:1929–1937

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217–2222

    Article  PubMed  Google Scholar 

  12. Shibli-Rahhal A, Vaughan-Sarrazin MS, Richardson K, Cram P (2011) Testing and treatment forosteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int 22:2973–2980

    Article  CAS  PubMed  Google Scholar 

  13. Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650–657

    Article  PubMed  PubMed Central  Google Scholar 

  14. National Committee for Quality Assurance (2013) The state of health care quality 2013. Improvingquality and patient experience. Available at: http://www.ncqa.org/Portals/0/Newsroom/SOHC/2013/SOHC-web_version_report.pdf. Accessed July 13, 2016

  15. American Academy of Orthopaedic Surgeons (2014) Osteoporosis/bone health in adults as a national public health priority. Position statement. Available at: http://www.aaos.org/about/papers/position/1113.asp. Accessed July 13, 2016

  16. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47:69–72

    Article  PubMed  PubMed Central  Google Scholar 

  17. Song X, Shi N, Badamgarav E, Kallich J, Varker H, Lenhart G, Curtis JR (2011) Cost burden of second fracture in the US health system. Bone 48:828–836

    Article  PubMed  Google Scholar 

  18. Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures. Ann Intern Med 161:711–723

    Article  PubMed  Google Scholar 

  19. Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29:1926–1928

    Article  PubMed  Google Scholar 

  20. Lems WF (2015) Fracture risk estimation may facilitate the treatment gap in osteoporosis. Ann Rheum Dis 74:1943–1945

    Article  PubMed  Google Scholar 

  21. MacLaughlin EJ (2010) Improving osteoporosis screening, risk assessment, diagnosis, and treatment initiation: role of the health-system pharmacist in closing the gap. Am J Health Syst Pharm 67(Suppl 3):S4–S8

    Article  PubMed  Google Scholar 

  22. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E, ASBMR Task Force on Secondary Fracture Prevention (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27:2039–2046

    Article  PubMed  Google Scholar 

  23. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, IOF Fracture Working Group (2013) Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mitchell PJ (2013) Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep 11:52–60

    Article  PubMed  Google Scholar 

  25. Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B, Eisman JA, Geusens PP, Brink PR (2014) Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am 96:e29

    Article  PubMed  Google Scholar 

  26. Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 27:873–879

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a research grant from Amgen Inc. The contract provides for the Minneapolis Medical Research Foundation authors to have final determination of manuscript content. Drs. Yusuf, Grauer, Barron, and Chandler are employed by Amgen. The authors thank Chronic Disease Research Group colleague Nan Booth, MSW, MPH, ELS, for manuscript editing.

Author information

Authors and Affiliations

  1. Amgen, Inc., Thousand Oaks, CA, USA

    Akeem A. Yusuf, Andreas Grauer, Richard Barron & David Chandler

  2. College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

    Akeem A. Yusuf

  3. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN, USA

    Thomas J. Matlon & Yi Peng

Authors
  1. Akeem A. Yusuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. Matlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Grauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Barron
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Chandler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akeem A. Yusuf.

Ethics declarations

We applied to and received approval from the Human Subjects Research Committee of the Hennepin County Medical Center/Hennepin Healthcare System, Inc.

Conflicts of interest

None.

Electronic supplementary material

ESM 1

(PDF 28 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yusuf, A.A., Matlon, T.J., Grauer, A. et al. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries. Arch Osteoporos 11, 31 (2016). https://doi.org/10.1007/s11657-016-0285-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11657-016-0285-0

Keywords

  • Fragility fracture
  • Medicare
  • Osteoporosis
  • Osteoporosis medication